2021 AACC Annual Scientific Meeting to Require Both Proof of COVID-19 Vaccination and Negative Test from All In-Person Attendees
|
By LabMedica International staff writers Posted on 31 Aug 2021 |

Illustration
The 2021 American Association for Clinical Chemistry (AACC; Washington, DC, USA) Annual Scientific Meeting & Clinical Lab Expo will be a live event with new location and dates, backed by plans to make the meeting a safe and productive one amidst the flare up in the COVID-19 pandemic.
This year's AACC Annual Scientific Meeting, held in partnership with the Canadian Society of Clinical Chemists, has moved from Anaheim to Atlanta due to stringent COVID-19 lockdown requirements in California, and the meeting dates have also moved by one week to September 26-30. In his latest email, AACC 2021 President Dr. Stephen Master, PhD, had outlined the extensive health and safety planning to make this year’s AACC Annual Scientific Meeting and Clinical Lab Expo in Atlanta a safe and productive in-person meeting. In order to ensure the safety of all attendees, the email clearly stated that unvaccinated people would not be permitted into the conference and expo campus without a current, negative SARS-CoV-2 antigen test or verified proof of vaccination.
As per its latest update, AACC now requires all meeting participants to be vaccinated, and for all meeting participants to have received a negative PCR or antigen COVID-19 test within 72 hours of arriving at the convention center. Proof of COVID-19 vaccination AND proof of a negative PCR or antigen coronavirus test will be required for in-person attendees of the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. Individuals who are unable to provide both of these things will not be permitted to enter the meeting and antibody test results will not be accepted.
Additionally, mask policies will be in place and strictly enforced. All persons within the AACC meeting campus must wear a face mask covering their nose and mouth at all times they are indoors. Moreover, detailed meeting logistics and design have been laid down to prevent crowding and disperse crowding at the event, and additional measures may be taken if required. Signage will be used to encourage social distancing, plexiglass separations will be placed at points of sale, and educational session times will be staggered to reduce the number of attendees in common areas.
“Our plans to hold a safe and productive in-person meeting in Atlanta have not changed,” wrote Dr. Stephen Master. “The meeting is on, and it will be safe.”
“I encourage you to check out the conference program if you haven’t already. And I look forward to seeing many of you in Atlanta next month,” he added.
Related Links:
American Association for Clinical Chemistry
This year's AACC Annual Scientific Meeting, held in partnership with the Canadian Society of Clinical Chemists, has moved from Anaheim to Atlanta due to stringent COVID-19 lockdown requirements in California, and the meeting dates have also moved by one week to September 26-30. In his latest email, AACC 2021 President Dr. Stephen Master, PhD, had outlined the extensive health and safety planning to make this year’s AACC Annual Scientific Meeting and Clinical Lab Expo in Atlanta a safe and productive in-person meeting. In order to ensure the safety of all attendees, the email clearly stated that unvaccinated people would not be permitted into the conference and expo campus without a current, negative SARS-CoV-2 antigen test or verified proof of vaccination.
As per its latest update, AACC now requires all meeting participants to be vaccinated, and for all meeting participants to have received a negative PCR or antigen COVID-19 test within 72 hours of arriving at the convention center. Proof of COVID-19 vaccination AND proof of a negative PCR or antigen coronavirus test will be required for in-person attendees of the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. Individuals who are unable to provide both of these things will not be permitted to enter the meeting and antibody test results will not be accepted.
Additionally, mask policies will be in place and strictly enforced. All persons within the AACC meeting campus must wear a face mask covering their nose and mouth at all times they are indoors. Moreover, detailed meeting logistics and design have been laid down to prevent crowding and disperse crowding at the event, and additional measures may be taken if required. Signage will be used to encourage social distancing, plexiglass separations will be placed at points of sale, and educational session times will be staggered to reduce the number of attendees in common areas.
“Our plans to hold a safe and productive in-person meeting in Atlanta have not changed,” wrote Dr. Stephen Master. “The meeting is on, and it will be safe.”
“I encourage you to check out the conference program if you haven’t already. And I look forward to seeing many of you in Atlanta next month,” he added.
Related Links:
American Association for Clinical Chemistry
Latest AACC 2021 News
- Study Showing Differing COVID-19 Antibody Profiles Among Vaccinated and Naturally Infected Individuals Presented at AACC 2021
- Study Reveals Varying Antibody Responses and Adverse Reactions Among Recipients of Different COVID-19 Vaccines
- Novel Study on Performance of Coronavirus Tests in Children Presented at 2021 AACC Annual Scientific Meeting
- New Rapid Test That Identifies Deteriorating COVID-19 Patients with Greater Accuracy than Existing Tests Presented at AACC 2021
- New Blood Test for Occupational Stress Identifies Healthcare Professionals Burned out from COVID-19 Pandemic
- New Non-Invasive Saliva Test for Early and Accurate Detection of Prostate Cancer Presented at AACC 2021
- New Non-Invasive Blood Test for Colon Cancer Presented at 2021 AACC Annual Scientific Meeting
- Study Establishing Accurate Reference Intervals for Pregnant Patients Presented at AACC 2021
- New Test that Measures Antibodies in Girls Who Have Received HPV Vaccine Presented at AACC 2021
- Novel Insights on COVID-19 Vaccines and Virus Evolution, AI in the Clinic, and Miniaturization of Diagnostic Platforms Explored at AACC 2021
- Seegene Unveils New STARlet-AIOS All-in-One Solution for All Molecular Testing at AACC 2021
- Group K Diagnostics Demonstrates KromaHealth Kit that Enables Lab-Quality Results at Point-of-Care
- NGeneBio Showcases NGS-Based Oncology/Genetic Diseases Kits and NGenePlex nCoV qRT-PCR Kit Against COVID-19
- Visby Medical Presents New Portable PCR COVID-19 Test Kit at 2021 AACC Annual Scientific Meeting & Clinical Lab Expo
- Fluxergy Introduces First-of-Its-Kind Multi-Modal Laboratory Platform That Diagnoses COVID-19 On-Site in 60 Minutes
- Mammoth Biosciences Presents AACC 2021 Disruptive Technology Award Finalist CRISPR-Based Detection Platform
Channels
Clinical Chemistry
view channel
Online Tool Detects Drug Exposure Directly from Patient Samples
Doctors often rely on patient interviews and medical records to determine what medications a person has taken, but this information is frequently incomplete. People may forget drugs they used, take over-the-counter... Read more
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read moreMolecular Diagnostics
view channel
New 15-Minute Hepatitis C Test Paves Way for Same-Day Treatment
Chronic hepatitis C infection affects an estimated 50 million people worldwide and causes around 242,000 deaths each year, largely due to cirrhosis and liver cancer. Although the infection is curable with... Read more
Ovarian Cancer Assay Outperforms Traditional Tests in Early Disease Detection
Globally, ovarian cancer is one of the deadliest cancers affecting women. Traditionally, early diagnosis of ovarian cancer has been challenging. Many ovarian cancers are diagnosed only after they have... Read moreHematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Blood Test Could Detect Adverse Immunotherapy Effects
Immune checkpoint inhibitors have transformed cancer treatment, but they can also trigger serious immune-related adverse events that damage healthy organs and may become life-threatening if not detected early.... Read more
Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read moreMicrobiology
view channel
Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
Lower-respiratory tract infections (LRTIs) are a leading cause of illness and death worldwide, and pneumonia is the leading infectious cause of death in children under five, claiming the lives of over... Read more
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channel
Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
Head and neck cancers are among the most aggressive malignancies worldwide, with nearly 900,000 new cases diagnosed each year. Monitoring these cancers for recurrence or relapse typically relies on tissue... Read more
Common Health Issues Can Influence New Blood Tests for Alzheimer’s Disease
Blood-based tests for Alzheimer’s disease are transforming diagnosis by offering a simpler alternative to spinal taps and brain imaging. However, many people evaluated at memory clinics also live with... Read more
Blood Test Formula Identifies Chronic Liver Disease Patients with Higher Cancer Risk
Chronic liver disease affects millions worldwide and can progress silently to hepatocellular carcinoma (HCC), one of the deadliest cancers globally. While surveillance guidelines exist for patients with... Read moreTechnology
view channel
Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease that is notoriously difficult to diagnose in its early stages. Early symptoms often overlap with other neurological... Read more
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read moreIndustry
view channel
BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) has entered into a strategic collaboration with the Institute for Immunology and Immune Health (I3H, Philadelphia, PA, USA) at the University... Read more










